Welcome to our dedicated page for AMRH news (Ticker: AMRH), a resource for investors and traders seeking the latest updates and insights on AMRH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMRH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMRH's position in the market.
Ameri Holdings, Inc. (NASDAQ: AMRH) announced a 1-for-4 reverse stock split, effective December 30, 2020. This decision follows stockholder approval at a special meeting on December 29, 2020. Ameri is set to acquire all outstanding shares of Jay Pharma, transitioning into a wholly-owned subsidiary. Following this transaction, Ameri will be renamed Enveric Biosciences, Inc., with the reverse split implemented. The company anticipates trading under the new symbol 'ENVB' on December 31, 2020. Share adjustments will reflect the split, affecting stock options and warrants accordingly.
Ameri Holdings (NASDAQ: AMRH) announced that its shareholders approved all proposals at a special meeting, enabling the completion of a tender offer for Jay Pharma. Ameri will acquire all outstanding shares of Jay Pharma in exchange for Ameri stock, with plans to finalize the offer by year-end, pending Nasdaq approval. Additionally, stockholders approved a spin-off of Ameri's IT services business. Following these transactions, Ameri will change its name to Enveric Biosciences and its ticker to ENVB.
Ameri Holdings, Inc. (NASDAQ: AMRH) has adjourned its Special Meeting of Shareholders originally scheduled for Dec. 23, 2020, to Dec. 29, 2020, at 9:00 am EST. Valid proxies submitted will remain effective for the rescheduled meeting. Ameri seeks stockholder approval for a proposed tender offer to acquire all outstanding shares of Jay Pharma. Following this, Ameri plans to spin off its IT services business before year-end, pending Nasdaq approval. Upon completion, Ameri will rebrand to Enveric Biosciences, Inc. and change its trading symbol to 'ENVB'.
Ameri Holdings (NASDAQ: AMRH) announced that the SEC has declared its Registration Statement on Form S-4 effective, paving the way for a proposed merger with Jay Pharma. A special meeting for stockholders is scheduled for December 23, 2020, to vote on the merger proposals. The completion of the transaction is contingent upon approval from stockholders of both companies, Nasdaq approval, and customary closing conditions. This merger represents the final step in a long-awaited reverse transaction, aimed at enhancing Ameri's position in the SAP services market.
Ameri Holdings, Inc. (NASDAQ: AMRH) has filed an Amended Registration Statement on Form S-4 with the SEC, which includes a preliminary proxy statement/prospectus for a proposed tender agreement with Jay Pharma. The Boards of Directors of both companies are committed to finalizing the reverse merger transaction. Once the Amended S-4 is effective, a special meeting will be scheduled for stockholders to vote on the merger. Following the completion, Ameri intends to rebrand as EXTEN Biosciences, Inc. and will continue trading on Nasdaq under a new ticker symbol.
On September 17, 2020, AMERI Holdings (NASDAQ: AMRH) filed a second amendment to its Registration Statement on Form S-4 with the SEC, including a preliminary proxy statement regarding a proposed tender agreement with Jay Pharma. The completion of the transaction awaits approval from both companies' stockholders and effective SEC registration. Following the closing, Ameri plans to rebrand as Jay Pharma, Inc. and will operate under a new ticker symbol on Nasdaq. Investors are advised to review the registration materials for crucial information.
On August 13, 2020, Ameri Holdings, Inc. (NASDAQ: AMRH) filed an Amended Registration Statement on Form S-4 with the SEC, including a preliminary proxy statement/prospectus regarding its proposed tender agreement with Jay Pharma. The transaction requires approval from both Ameri and Jay Pharma stockholders and the SEC's declaration of the Registration Statement. Upon closing, Ameri will change its name to Jay Pharma, Inc. and adopt a new ticker symbol while remaining listed on Nasdaq. Further documents will be made available to shareholders.
On July 29, 2020, AMERI Holdings, Inc. (NASDAQ: AMRH) announced its proposed amalgamation with Jay Pharma Inc. Jay Pharma is set to file two IND applications for treatments aimed at radiodermatitis and glioblastoma multiforme (GBM). Key leadership appointments include Dr. Robert Wilkins as Chief Medical Officer and Dr. Steven Weisman as part of the regulatory team. The GBM clinical trial in Israel will involve 40 participants, assessing a proprietary CBD formulation. The company aims to navigate FDA processes efficiently, marking a significant growth phase for Jay Pharma.
AMERI Holdings, Inc. (NASDAQ: AMRH) is advancing through regulatory reviews for a proposed amalgamation with Jay Pharma, a Canadian company focused on cannabinoid products for cancer care. This transaction includes the spin-off of Ameri's IT services to a private entity established by its management. Shareholder approval and Nasdaq concurrence are still required, delaying the expected closure from the first half of 2020. Ameri has filed a Registration Statement with the SEC regarding these proposals and plans to hold a special meeting for shareholders pending necessary approvals.
